key: cord-1012383-7p0f0s4b
authors: Revon-Riviere, Gabriel; Ninove, Laetitia; Min, Victoria; Rome, Angélique; Coze, Carole; Verschuur, Arnauld; de Lamballerie, Xavier; André, Nicolas
title: BNT162b2 mRNA Covid-19 Vaccine in AYA with cancer: a monocentric experience
date: 2021-06-23
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2021.06.002
sha: 66f723671f40832110e3f7fdef04791ad7c22dae
doc_id: 1012383
cord_uid: 7p0f0s4b

BACKGROUND AND AIMS: COVID-19 infection in pediatric cancer patients is severe or critical in 20% of the patients. It can therefore directly affect pediatric cancer patients and/or their care. We aimed at evaluating the safety and efficacy of BNT162b2 mRNA Covid-19 vaccine in AYA with solid tumor. METHODS: Retrospective analysis of safety and efficacy of BNT162b2 mRNA Covid-19 vaccine administered to patients, >= 16 years old, under treatment for a solid tumor or within 6 months’ post-treatment from 15/2/2021 to 15/4/2021. Two administrations of the vaccine 3 weeks apart were given. Sera were tested for anti-SARS-Cov-2 IgG antibodies directed against the S1 domain of the spike protein. In case of positive serology, neutralization of SARS-Cov-2 was tested. RESULTS: Twenty-three patients with solid tumors were identified and proposed to get vaccinated. Nine patients refused and 1 previously developed COVID-19 infection with positive serology. At time of writing, 13 patients (10 M/2F); median age: 17) started vaccination. All patient received 2 injections except 2 patients who stopped vaccination because of tumor progression. Ten patients were under treatment (chemotherapy-7pts, immunotherapy-2 pts, targeted therapy-2 pts-follow-up 3 patients). Overall, vaccines were well tolerated. Five patients did not report any side-effect after the first injection and 4 after the second injection. Main local reactivity symptom was mild pain at the site of injection (6 and 2 pts). Fatigue (2pts and 5 pts) was the most frequent systemic symptom. One patient refused serology testing. All patients but 1 had pre-vaccination negative serology, 7/10 tested had positive serology before second vaccine injection, 9/10 had positive serology one month after the second injection. All patients with seroconversion had positive COVID-19 neutralization test. No patient developed COVID infections. CONCLUSIONS: We report the good safety profile and good efficacy BNT162B2 vaccine in AYA with solid tumors. Larger series and monitoring of the kinetics of anti-Sars-Cov-2 IgG antibodies for several months are mandatory to confirm these preliminary results and to determine long-term vaccination.

Since its beginning, the COVID-19 pandemic has gradually directly and indirectly affected patients with chronic disease worldwide 1 . Although children are at lower risk of developing severe form of COVID-19 2 , children treated for malignancies may be at higher risk of developing severe forms as compared to their healthy counterparts 2-5 . The global registry of COVID-19 in Childhood Cancer 6 reports 20% of severe and critical forms among 1500 patients. Direct and indirect consequences of COVID-19 such as delays in diagnosis or treatment can impact of outcome of these patients 7 . For children receiving experimental therapies, data are even rarer and physician have been very cautious. The ITCC have thus reported a 60% decrease of enrolment of patients in early phase clinical trials in Europe 7

Despite initial hope in drug repurposing, medical treatments such as chloroquine have largely failed to help clearing the virus, although the use of heparin, steroids and oxygen have greatly helped to improve outcome of patients 9-11 . As for today, beyond social distancing, vaccines are the main tools to prevent further spread of the pandemic and protect people from the infection 12 .

We report here a monocentric retrospective monocentric experience with the RNAm vaccine in Adolescent and Young Adults (AYA) with solid malignancies under treatment or 6 months after completion of treatment treated in our department.

Population: AYA older than 16 years old, under treatment for their malignancies or who had completed their treatment within 6 months and followed in the department of Pediatric Immunology, hematology and oncology, of the children hospital of La Timone, AP-HM were proposed to receive the BNT162b2 mRNA Covid-19 Vaccine.

Treatment: Patients were planned to receive two doses, 21 days apart, of the BNT162b2 vaccine (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein 12

Methods: Sera samples were tested for anti-SARS-Cov-2 IgG antibodies directed against the S1 domain of the spike protein of the virus using a commercial ELISA kit (Euroimmun®, Luebeck, Germany) as recommended by manufacturer. All samples with an ELISA ratio ≥0.7, neutralizing antibodies against SARS-Cov-2 were detected using a virus neutralization test (VNT100), as previously described 13 . Serial dilutions of sera 1/10 to 1/160 were tested and specimen with VNT100 titer ≥40 were considered positive, those with titer at 20 indeterminate and <20, negative. Samples were taken before first administration (T0), before second administration (T1) one month after the second administration of the vaccine (T2).

J o u r n a l P r e -p r o o f Ethic: All data have been generated as part of the routine care at Assistance Publique-Hôpitaux de Marseille, and this study results from routine clinical management. The study was approved by the AP-HM, and access to the patients' biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hôpitaux de Marseille (APHM PADS21-136). All patients signed informed consent.

Twenty-three patients were identified and proposed the BNT162b2 mRNA Covid-19 Vaccine. Out of these 23 patients, 9 refused to receive the vaccine. The reason for refusal were the fear of developing sides effect, the lack of long-term knowledge about tolerance for 8 patients and living too far from the hospital for 1 patient. One patient did not receive the vaccine as he already had developed COVID-19 14 and still displayed positive serology and positive virus neutralization test.

Therefore, 13 patients started vaccination (see Figure 1 ). The characteristics of these 13 patients are given in table 1. Patients were receiving chemotherapy (7 patients), targeted therapies (2 patients), or immunotherapies (2 patients) alone or in combination. Three patients were in followup.

Two patients did not receive the second injection because of tumor progression and also lived far away from our institution. They received palliative care only.

Overall, vaccines were well tolerated. Five out of 13 patients did not report any sides effect after the first injection and 4 out of 11 after the second injection. The most frequent side effect was a mild-to-moderate pain at the injection site (6 patients) that resolved within 1 to 2 days. The second administration seemed to be slightly less well tolerated with more frequent systemic reactions. Details of sides effects are reported in table 2. Systemic events including fever and chills were observed within the first 1 to 2 days after vaccination and resolved shortly thereafter. Aside from transient local and systemic reactions, no safety concerns were identified.

All patient but one were negative for COVID-19 serology before immunization. This patient did not previously develop COVID-19 symptoms and the second serology was negative. Overall, 3 weeks after the first the injection 8/10 tested patient developed seroconversion and one month after the second administration, the vaccine led to a seroconversion in 9/10 tested patients with positive COVID neutralization test in all. The only patient with negative serology 1 months after the second serology had a positive serology at the time of the second injection and positive seroneutralisation. No patients developed COVID after immunization.

We report here, our experience with the immunization with a COVID-19 mRNA vaccine of AYA under treatment or shortly after completion of treatment for a solid tumor. Our results show a J o u r n a l P r e -p r o o f high rate of refusal, a good tolerance and a high immunogenicity in a real life setting of immunocompromised pediatric patients. To the best of our knowledge, our results are the first reported in AYA with cancer, it is therefore impossible to compare it with other experiences.

Adverse events are consistent with those previously reported in healthy AYA 12 .

Preliminary studies reported that healthy children and adolescents under the age of 15 vaccinated against sars-Cov-2 have a very high rate of protection compared to a healthy adult. In cancer patients, only adult data is reported. The series we report here has some limitations. We studied a small number of patients in a single center. Patients were limited to AYA with solid tumor and therefore, do not reflect the majority of the pediatric oncology patients. In addition, the study was conducted over a short period up to one month after the second dose of vaccine, it would be necessary to continue monitoring the kinetics of anti-sars-Cov-2 IgG antibodies for several in order to assess vaccine protection over time.

If our preliminary results are confirmed, such a vaccine could be proposed to AYA before the initiation of their treatment and during treatment to prevent severe forms of Covid-19 or additional complications related to the disease that may compromised their oncologic treatment and in turn their long-term outcomes.

Close follow-up remains mandatory to detect rare or unknown sides effect of the vaccine in this very specific population or interactions with oncologic treatment or procedures such as radiation recall 16 It is therefore crucial that adequate information and education is brought to pediatric cancer patients and their family to increase enrollment in vaccination programs and in turn the success of the campaign. Education strategies must be developed with respect to AYA specific needs and J o u r n a l P r e -p r o o f habits, for example trough social media 21 or webinars 22 to make it happen as urged by Curigliano G and Eggermont 23

We report here a preliminary experience with RNA vaccines in AYA with solid tumors and report a good safety profile and excellent immunogenicity. Larger series and monitoring of the kinetics of anti-Sars-Cov-2 IgG antibodies for several months are mandatory to confirm these preliminary results and to determine long-term vaccination effect. 

Heparin as a therapy for COVID-19: current evidence and future possibilities

C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors

Favorable Outcome of COVID-19

Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

OVID-19 Vaccine-Induced Radiation Recall Phenomenon

Even-Sapir E Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation

SARS-CoV-2 vaccines for cancer patients: a call to action

The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey

Vaccine Enthusiasm and Hesitancy in Cancer Patients and the Impact of a Webinar

Lantos JD Promoting COVID-19 Vaccination on Social Media. Pediatrics